Active, Not Recruiting
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors - CA223-030
Updated: 14 May, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com - Participants must have histologic or cytologic confirmation of a solid malignancy that is advanced (metastatic and/or unresectable) - Presence of at least 1 lesion with measurable disease as defined by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria for response assessment - The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: - Participants with untreated central nervous system (CNS) metastases - Participants with an active, known, or suspected autoimmune disease - Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information